Merck
May 2013
Today, a group of public and private sector partners announced an agreement that will expand contraceptive access and options for millions of women in some of the world’s poorest countries. Under the agreement, Merck will reduce the cost of IMPLANON® – a singlerod, long-acting, reversible contraceptive implant – and its next generation implant, IMPLANON NXT® (marketed in some countries as Nexplanon®), by approximately 50 percent for the next six years in the targeted poorest eligible countries of focus for the reproductive health community…
The organizations involved – including Merck and the Bill & Melinda Gates Foundation as direct parties to the agreement, and the Clinton Health Access Initiative, the governments of Norway, the United Kingdom, the United States and Sweden, the Children’s Investment Fund Foundation and the United Nations Population Fund (UNFPA) as facilitating parties – established this arrangement in response to strong demand for long-acting, reversible contraceptive options in developing countries.